ClinicalTrials.gg
CompletedNCT02152969Updated Nov 19, 2014

Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)

A Phase 1 interventional study of Telmisartan and Amlodipine in Hypertension, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-19.

Sponsored by Yuhan Corporation · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
71st of 99
66 · median 184
Started
2014
with 3 others
Phase 1
15 of 99
none open now
Registered
54th of 99
by date
Lead sponsor
2 of 99
Yuhan Corporation

Among the 99 studies testing telmisartan in Hypertension, this one is the 71st largest by enrollment, is one of 4 that started in 2014, is one of 15 in phase 1, and was the 54th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

To evaluate Drug-drug interaction

Read the detailed description

The purpose of this study is to evaluate the Drug-Drug(telmisartan, amlodipine and/ or chlorthalidone) interaction and safety in healthy adult volunteers.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant who has a body weight that is ≥55kg(male) or ≥50kg(female) with ideal body weight of 80-120% (ideal body weight)
  2. Who has not suffered from disease
  3. Provision of signed written

Exclusion criteria

Exclusion Criteria:

  1. History of and disease psychiatric, or .
  2. A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs.
  3. Administration of other products within 3 months prior to the first dosing.
  4. Administration of herbal medicine within 2 weeks or administration of ethical drugs within 2 weeks or administration of over-the-counter (OTC) drugs within 1 week prior to the first dosing of the investigational product (if the investigator (study doctor) determines that the person meets other criteria appropriately, the relevant person may participate in the study).
  5. Volunteers considered not eligible for the clinical trial by the investigator (study doctor) due to reasons including laboratory test results, ECGs, or vital signs.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Other
    Part B

    Arm to evaluate influence of Chlorthalidone on pharmacokinetics of amlodipine and telmisartan.

    Drug: Telmisartan · Drug: Amlodipine · Drug: Chlorthalidone

  • Other
    Part A

    Arm to evaluate influence of amlodipine and telmisartan on pharmacokinetics of Chlorthalidone.

    Drug: Telmisartan · Drug: Amlodipine · Drug: Chlorthalidone

Interventions

06

What researchers measure

Primary outcomes

  1. AUCt ss, Cmax ss of telmisartan/amlodipine/chlorthalidone

    Time frame: Totally 28points for 24 hours

Secondary outcomes

  1. Cmin ss, tmax ss, t1/2 of telmisartan/amlodipine/chlorthalidone

    Time frame: Totally 28points for 24 hours

07

Study locations

1 site
  • The Catholic University of Korea Seoul St.Mary's Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Aug 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2014
First posted
Jun 2, 2014
Start
May 2014
Primary completionActual
Aug 2014
CompletionActual
Nov 2014
Last update
Nov 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02152969
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Jun 2, 2014
Start date
May 2014
Primary completion
Aug 2014
Completion
Nov 2014
Last update
Nov 19, 2014

Study contacts

Dong Seok Yim
principal investigator · The Catholic University of Korea

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine · Chlorthalidone

Start the discussion